🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study

RecruitingNAAges 18 Years - anyFemaleGynaecologisch Oncologisch Centrum Zuid
NCT06611072 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Ovarian cancer (OC) is one of the most lethal cancers in the world due to late-stage disease at diagnosis. Standard therapy consists of debulking surgery and chemotherapy. However, despite this aggressive treatment, recurrent disease almost invariably occurs resulting in a five-year survival rate of approximately 30%. Immunotherapy could be a way to increase survival in OC patients. However, a major barrier to a successful deployment of cancer immunotherapy for ovarian cancer patients is the immunosuppressive tumor microenvironment. Envisioned solution/research direction Tumor-related inflammation is one of the hallmarks of cancers in general. Innate immunity specifically is a common denominator that is involved in the pathogenesis of OC. To improve the patient's outcome and identify novel therapeutic targets, one needs a deeper understanding of the tumor-induced changes in the bone m

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Subjects should be at least 18 years old and mentally competent; * Newly diagnosed patients with OC who go for primary debulking surgery or patients with OC who are scheduled for interval debulking; * Controls: women who undergo surgery for benign gynaecological conditions under general anaesthesia. Exclusion Criteria: * Mentally incompetent; * Pregnant or breastfeeding; * Known inflammatory of infectious diseases or an immunosuppressive status; * Using medication interfering with the immune system; * Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas); * Serious psychiatric pathology; * A self reported alcohol consumption of \>21 units per week.
💊

What it tests

  • Bone marrow aspiration
  • Vena puncture
  • Peritoneal fluid
  • Spleen biopsy
  • Tumor biopsy
📍

Where

1 site
Catharina Hospital
Eindhoven, Netherlands
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy